84 related articles for article (PubMed ID: 17102586)
21. Endogenous MHC class II processing of a viral nuclear antigen after autophagy.
Paludan C; Schmid D; Landthaler M; Vockerodt M; Kube D; Tuschl T; Münz C
Science; 2005 Jan; 307(5709):593-6. PubMed ID: 15591165
[TBL] [Abstract][Full Text] [Related]
22. The role of tetraspanin CD63 in antigen presentation via MHC class II.
Petersen SH; Odintsova E; Haigh TA; Rickinson AB; Taylor GS; Berditchevski F
Eur J Immunol; 2011 Sep; 41(9):2556-61. PubMed ID: 21660937
[TBL] [Abstract][Full Text] [Related]
23. Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.
Murray RJ; Kurilla MG; Griffin HM; Brooks JM; Mackett M; Arrand JR; Rowe M; Burrows SR; Moss DJ; Kieff E
Proc Natl Acad Sci U S A; 1990 Apr; 87(8):2906-10. PubMed ID: 2158098
[TBL] [Abstract][Full Text] [Related]
24. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
Gregory CD; Rowe M; Rickinson AB
J Gen Virol; 1990 Jul; 71 ( Pt 7)():1481-95. PubMed ID: 2165133
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells.
Mautner J; Pich D; Nimmerjahn F; Milosevic S; Adhikary D; Christoph H; Witter K; Bornkamm GW; Hammerschmidt W; Behrends U
Eur J Immunol; 2004 Sep; 34(9):2500-9. PubMed ID: 15307182
[TBL] [Abstract][Full Text] [Related]
26. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1.
Wrightham MN; Stewart JP; Janjua NJ; Pepper SD; Sample C; Rooney CM; Arrand JR
Virology; 1995 Apr; 208(2):521-30. PubMed ID: 7538250
[TBL] [Abstract][Full Text] [Related]
27. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
28. Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes.
Rochford R; Hobbs MV; Garnier JL; Cooper NR; Cannon MJ
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):352-6. PubMed ID: 8380497
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus (EBV) latent membrane protein 1 increases HLA class II expression in an EBV-negative B cell line.
Zhang Q; Brooks L; Busson P; Wang F; Charron D; Kieff E; Rickinson AB; Tursz T
Eur J Immunol; 1994 Jun; 24(6):1467-70. PubMed ID: 8206105
[TBL] [Abstract][Full Text] [Related]
30. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.
Gavioli R; De Campos-Lima PO; Kurilla MG; Kieff E; Klein G; Masucci MG
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5862-6. PubMed ID: 1321426
[TBL] [Abstract][Full Text] [Related]
31. Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1.
Steigerwald-Mullen P; Kurilla MG; Braciale TJ
J Virol; 2000 Aug; 74(15):6748-59. PubMed ID: 10888613
[TBL] [Abstract][Full Text] [Related]
32. Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines.
Yoo L; Speck SH
J Virol; 2000 Dec; 74(23):11115-20. PubMed ID: 11070007
[TBL] [Abstract][Full Text] [Related]
33. Autophagy in MHC class II antigen processing.
Strawbridge AB; Blum JS
Curr Opin Immunol; 2007 Feb; 19(1):87-92. PubMed ID: 17129719
[TBL] [Abstract][Full Text] [Related]
34. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus.
Ernberg I; Falk K; Minarovits J; Busson P; Tursz T; Masucci MG; Klein G
J Gen Virol; 1989 Nov; 70 ( Pt 11)():2989-3002. PubMed ID: 2479717
[TBL] [Abstract][Full Text] [Related]
35. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.
Leen A; Meij P; Redchenko I; Middeldorp J; Bloemena E; Rickinson A; Blake N
J Virol; 2001 Sep; 75(18):8649-59. PubMed ID: 11507210
[TBL] [Abstract][Full Text] [Related]
36. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Moss DJ; Kurilla MG; Cooper L
Int Immunol; 1997 Oct; 9(10):1537-43. PubMed ID: 9352359
[TBL] [Abstract][Full Text] [Related]
37. T cell recognition of Epstein-Barr virus associated lymphomas.
Rickinson AB; Murray RJ; Brooks J; Griffin H; Moss DJ; Masucci MG
Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells.
Rasul AE; Nagy N; Sohlberg E; Ádori M; Claesson HE; Klein G; Klein E
J Immunol Methods; 2012 Nov; 385(1-2):60-70. PubMed ID: 22921685
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxic T lymphocyte discrimination between type A Epstein-Barr virus transformants is mapped to an immunodominant epitope in EBNA 3.
Misko IS; Schmidt C; Moss DJ; Burrows SR; Sculley TB
J Gen Virol; 1991 Feb; 72 ( Pt 2)():405-9. PubMed ID: 1704413
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23.
Wang F; Gregory CD; Rowe M; Rickinson AB; Wang D; Birkenbach M; Kikutani H; Kishimoto T; Kieff E
Proc Natl Acad Sci U S A; 1987 May; 84(10):3452-6. PubMed ID: 3033649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
